CRIS

0.42709.03%
MD

Martyn D. Greenacre

Independent Chairman of the Board

Mr. Martyn D. Greenacre, MBA, serves as the Chairman and Chief Executive Officer at Life Mist Inc. Mr. Greenacre has been Chief Executive Officer of Life Mist LLC since September 2001 and has been its Chairman since 2002. He served as Chief Executive Officer of Delsys Pharmaceutical Corp. from June 1997 to June 2001 and served as its President. From March 1993 to 1997, Mr. Greenacre served as President and Chief Executive Officer of Zynaxis Inc. and also was its Principal Accounting Officer. He joined SmithKline & French in 1973, where he held positions of increasing responsibility for the strategic direction and operational management of all pharmaceutical subsidiaries in Western Europe and for the execution of the merger of SmithKline Beecham Corp. and Beecham Group PLC, pharmaceutical operations in Europe. From 1983 to 1989, Mr. Greenacre served as Vice President, Continental Europe and SmithKline & French Pharmaceuticals. Mr. Greenacre was responsible for a critical acquisition, divesting a non-performing business and negotiating a strategic merger. He served as Senior Advisor of Arsenal Capital Partners, Inc. He serves as Chairman and Director of Life Mist Technologies, Inc. He serves as an Independent Chairman of the Board at Curis, Inc., since May 2017. He had been the Chairman of Acusphere, Inc. since March 2011. Mr. Greenacre served as Chairman of BMP Sunstone Corporation (formerly Beijing Med-Pharm Corporation) since July 2004 and served as its Director since 2004. He served as Chairman of Zynaxis Inc. since April 1993. From July 1989 to June 1992, Mr. Greenacre served as Chairman Europe, SmithKline Beecham Pharmaceuticals. He served as the Chairman of the Board and Director of Delsys Pharmaceutical Corp. He has been an Independent Director of Curis, Inc. since February 2000. Mr. Greenacre joined the Curis, Inc. in February 2000. He had been a Director of Acusphere Inc. since July 2001. He served as a Director of Cephalon, Inc. since 1992. From March 1993 to 1997, he served as a Director of Zynaxis Inc. He served as a Director of Serono Genetics Institute S. A. (formerly, Genset) since 1993. From June 1993 to July 2000, he served as a Director of Creative BioMolecules, Inc. He served as an Independent Director of Caladrius Biosciences, Inc. (formerly Neostem, Inc.), from December 08, 2011 to July 14, 2015. He served as a Director of Orchestra Therapeutics, Inc. (formerly Immune Response Corp.) since June 19, 2003. He served as a Director of Theorem Clinical Research (formerly, Omnicare Clinical Research, Inc. and IBAH Inc.) since April 1994. He served on the Board of the Association of British Pharmaceutical Industry. Mr. Greenacre received a BA in Politics and Economics from Harvard College and an MBA from Harvard University, Graduate School of Business Administration. He had been a Director at Formula Pharmaceuticals, Inc. since January 2012.

Positions